What happened
Life Biosciences announced interim Phase 1 data for ER-100, an epigenetic restoration therapy, in three participants with open-angle glaucoma. The therapy was well-tolerated through Day 56, and two participants showed preliminary visual field improvements. The Data Safety Monitoring Board recommended escalation to Dose Level 2.
“While this Phase 1 study is designed to evaluate safety and tolerability, the preliminary observations of visual field improvements in two participants are encouraging” — Sharon Rosenzweig-Lipson, Ph.D., Chief Scientific Officer of Life Bio
Plain-English summary written by an AI model from the Lifespan.io story; the quote is copied word for word from it.
The original
- Headline
- Life Biosciences Announces First-in-Human Phase 1 Trial Data
- From
- Lifespan.io (news report)
- Published
- Oct 27, 2026
Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, announced interim data from its Phase […]